MARATTO

article · Pan African Journal of Life Sciences

Elevated Inflammatory Markers in Type-2 Diabetes Mellitus Exacerbated by COVID-19

Abstract

Background: Type-2 Diabetes mellitus is a chronic systemic disease characterized by an increased blood glu-cose concentration which may be due to decreased effect of insulin on target tissues. blood glucose concentra-tion which may be due to decreased effect of insulin on target tissues. Several retrospective studies in Wuhan indicated that diabetes was one of the most prevalent comorbidities in COVID-19 patients. The effects of this comorbidity on inflammatory markers in southwest Nigeria are a serious health concern. Methods: This multicenter cross-sectional study investigated inflammatory markers in 400 participants catego-rized into distinct groups, including Type-2DM subjects without a history of COVID-19, COVID-19-recovered T2DM subjects at the onset of recovery (0 Month), COVID-19-recovered T2DM subjects three months post-recovery (3 Month), COVID-19-recovered subjects without T2DM, and apparently healthy controls. Blood samples were collected and analyzed for plasma Hs-Crp, D-dimer, and C-peptide using immuno-turbidimetry and Interleukin-6 levels using ELISA in all groups. Results: Results were interpreted by one-way ANOVA with post-hoc Tukey’s tests, which were used to com-pare the various groups in the study. Participants with T2DM recovering from COVID-19 exhibited significant-ly elevated levels of High Sensitivity C-Reactive Protein (HsCRP) (4.19 ± 0.67 mg/L), C-Peptide (4.84 ± 0.89 ng/ml), Interleukin-6 (IL-6) (46.01 ± 7.21 pg/ml), and D-Dimer (1.19 ± 0.43 mg/L) compared to healthy con-trols (p < 0.001). Three months post-recovery, these markers significantly decreased (p < 0.001), indicating a resolution of inflammatory responses. Correlation analysis revealed significant positive associations between glycemic control and inflammatory markers (p < 0.001). Conclusion: These findings underscore the exacerbated inflammatory responses in COVID-19 patients with T2DM and highlight the dynamic nature of inflammation during recovery.

Research topics

  • Adipokines, Inflammation, and Metabolic Diseases
  • Cardiovascular Disease and Adiposity
  • COVID-19 Clinical Research Studies

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.36108/pajols/4202/80.0330

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.